Riferminogene pecaplasmide

Drug Profile

Riferminogene pecaplasmide

Alternative Names: Cardiovascular gene therapy - sanofi-aventis; Cardiovascular therapeutic protein - sanofi-aventis; DNA-based delivery of Fibroblast Growth Factor 1 (FGF-1) - sanofi-aventis; FGF-1 gene therapy; NV1-FGF; Riferminogen pecaplasmid; Temusi; XRP 0038

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vical
  • Developer Sanofi; sanofi-aventis
  • Class Anti-ischaemics; Gene therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemic heart disorders; Peripheral arterial disorders

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Australia (IM)
  • 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Belarus (IM)
  • 31 Dec 2010 Discontinued - Phase-III for Peripheral arterial disorders in Argentina (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top